Atlas Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Atlas Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-371	Closed	-$47.4K	–	1103
2026 Q1	$47.4K	Buy	+371	New	+$46.3K	0.01%	651
2022 Q4	–	Sell	-97	Closed	-$7.69K	–	958
2022 Q3	$7.69K	Buy	+97	New	+$8.18K	﹤0.01%	738
2022 Q2	–	Sell	-97	Closed	-$8.72K	–	1030
2022 Q1	$8.72K	Sell	97 -299	-76%	-$27.6K	﹤0.01%	721
2021 Q4	$44.3K	Buy	396 +63	+19%	+$7.6K	0.01%	543
2021 Q3	$41.9K	Buy	333 +33	+11%	+$4.25K	0.01%	538
2021 Q2	$40.6K	Buy	300 +230	+329%	+$30.2K	0.01%	552
2021 Q1	$9.49K	Sell	70 -300	-81%	-$44.9K	﹤0.01%	685
2020 Q4	$52.1K	Buy	+370	New	+$47.4K	0.01%	463
2020 Q3	–	Sell	-500	Closed	-$56K	–	602
2020 Q2	$56K	Buy	+500	New	+$49.2K	0.01%	466
2019 Q3	–	Sell	-100	Closed	-$8.77K	–	702
2019 Q2	$8.77K	Buy	+100	New	+$8.53K	﹤0.01%	602

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Atlas Capital Advisors's XBI Position: Q2 2026 in Review

Atlas Capital Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2026, closing a stake of 371 shares — an estimated $47.4K sold.

Atlas Capital Advisors first reported a position in XBI in Q2 2019 and held it in 10 quarters. The position peaked at $56K in Q2 2020. 936 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Atlas Capital Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2026 after selling out during the quarter.
Atlas Capital Advisors sold 371 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $47.4K.
Atlas Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2019 and held it in 10 quarters.
Atlas Capital Advisors's State Street SPDR S&P Biotech ETF position peaked at $56K in Q2 2020.
936 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.